Shares of companies involved in psychedelic-tied therapies surged Monday after President Donald Trump signed an executive order to expedite research and access. US-traded shares of Compass Pathways spiked as much as 53% while AtaiBeckley surged by 37%. GH Research jumped 34% and Definium Therapeutics rallied 16%. The AdvisorShares Psychedelics ETF (PSIL) also climbed as much as 20% — touching its
Compass Pathways CEO on Trump's Order to Expand Psychedelics Research
Bloomberg Markets·Bloomberg Markets··1 min readLimited
B
Continue reading on Bloomberg Markets
This article was sourced from Bloomberg Markets's RSS feed. Visit the original for the complete story.
Limited free access — this source offers metered access before requiring a subscription.